source
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.Fierce Biotech · 9h ago↗ source
- Boulevard Bio raises $65M to expand immunology pipeline, eyes Vera's IgAN candidateBoulevard Bio announced it has secured $65 million in financing to broaden its immunology portfolio. The new capital will support the development of two immune‑resetting drugs the company discovere…